Dose-intense cyclophosphamide and etoposide for patients with refractory or high-risk non-Hodgkin's lymphoma.
Talbot
Jeffrey
J
Department of Medicine, Division of Medical Oncology and Stem Cell Transplantation, Duke University Medical Center, Durham, NC 27710, USA.
Ibom
Valerie K
VK
Rizzieri
David A
DA
Barrier
Robert
R
Niedzwieki
Donna
D
DeCastro
Carlos M
CM
Moore
Joseph O
JO
Buckley
Patrick
P
Laney
Rhonda
R
Stevenson
Diane
D
Rumbaugh
Heather
H
Gockerman
Jon P
JP
D000328:Adult; D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage*; D019008:Drug Resistance, Neoplasm; D005047:Etoposide / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D012306:Risk; D013997:Time Factors; D016896:Treatment Outcome
D018906:Antineoplastic Agents, Alkylating; D000972:Antineoplastic Agents, Phytogenic; D005047:Etoposide; D003520:Cyclophosphamide